No Data
No Data
Healthcare Sector Flexes Earnings Muscle, but Top-line Cracks Show
Gilead and Vertex Pharma Named Among Biotech's Tariff Safe Havens
Earnings Outlook For Vertex Pharmaceuticals
RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $320
Amgen Analyst Ratings
Mettler-Toledo Outlines 2025 EPS Guidance Amid Ongoing Tariff Challenges